FDA: BioDelivery Sciences Should Improve “Safe Use” REMS Provisions For Oral Fentanyl Approval

Onsolis “complete response” letter is “as close to approval as one can get without having it,” BDSI CEO says.

More from Archive

More from Pink Sheet